Werngard Czechtizky
AstraZeneca
Department of Medicinal Chemistry
Development of Oral and Inhaled Compounds for Respiratory Diseases – Case Studies
📅 April 23, 2026
🕒 11 : 00
📍 Heinzel Seminar Room | Office Building West
Coffee, beverages & snacks are served 30 min before the talk in front of the seminar room
Prof. Werngard Czechtizky has been Head of Medicinal Chemistry at AstraZeneca, Respiratory and Immunology. She has a track record of delivery of clinical candidates and lead compounds across several therapeutic areas (CV, Diabetes, Pain, CNS, Aging, Respiratory and Immunology). She implemented state of the art technologies into Medicinal Chemistry, e.g. ML/AI tools, New Modalities, targeted delivery, chemical probes for target validation, automated synthesis and integrated physchem & eADME profiling workflows. Werngard serves on diverse scientific advisory boards and is co-/author of >100 publications and patents. She has studied at the Technical University of Graz, Austria, received a PhD from ETH Zürich and a postdoctoral training at Harvard University. Before joining AZ in 2017, she has been working at Aventis, then Sanofi at Frankfurt, Germany. Her work bridges cutting-edge medicinal chemistry with advanced technologies such as AI/ML, novel modalities, and targeted delivery. With a strong track record of translating biological insights into clinical candidates, she offers valuable perspectives on how interdisciplinary research can drive real therapeutic impact.
Chemistry Colloquia are open to all and usually take place on Thursdays at 11:00 am (typically twice a month).
PhD students and postdocs are especially encouraged to attend!
Find instructions on how to get to the ISTA campus here.
